Jump to content

Talk:External reference pricing

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by Signimu (talk | contribs) at 18:10, 11 December 2019 (→Make a new "medicines prices" article and merge some of the content here: extend description of the monograph). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
WikiProject iconPharmacology Stub‑class Low‑importance
WikiProject iconThis article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology
StubThis article has been rated as Stub-class on Wikipedia's content assessment scale.
LowThis article has been rated as Low-importance on the project's importance scale.
WikiProject iconEconomics Unassessed
WikiProject iconThis article is within the scope of WikiProject Economics, a collaborative effort to improve the coverage of Economics on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.EconomicsWikipedia:WikiProject EconomicsTemplate:WikiProject EconomicsEconomics
???This article has not yet received a rating on Wikipedia's content assessment scale.
???This article has not yet received a rating on the project's importance scale.

Map of countries implementing ERP?

Would be nice to have a map of all countries implementing ERP in their drug cost-containement policies. --Signimu (talk) 00:29, 28 November 2019 (UTC)[reply]

 Done --Signimu (talk) 16:57, 28 November 2019 (UTC)[reply]

More resources on BRICS

A few more resources: [1][2][3][4][5][6][7], but it would be nice to dig further to find documentation on BRICS in particular. For instance, Russia implemented ERP as their main drug price criterion since Jan 2019 (under the name of "international benchmarking analysis" here: [8]), that's quite new and uncovered in the reviews I've found. --Signimu (talk) 16:59, 28 November 2019 (UTC)[reply]

Make a new "medicines prices" article and merge some of the content here

The content in this article should maybe be moved to Medication costs that is broader in its scope, using the references provided below. Some of the material that could be moved over includes for example the prices supply chain taxonomies, that are not specific to the external reference pricing measure. --Signimu (talk) 19:02, 9 December 2019 (UTC)[reply]

Here are interesting reports on a snapshot of the price and availability of medines for non-communicable diseases[9][10], this is surely interesting but I'm not sure this belongs here, maybe in another (connex) article? --Signimu (talk) 22:41, 28 November 2019 (UTC)[reply]
This source is excellent for all infos on pharmaceutical industries commercial and marketing strategies and evolution over time (look for "evergreening" for example), this source should be further exploited for this or other articles:[11]. --Signimu (talk) 21:17, 30 November 2019 (UTC)[reply]
The previous ref[1] should be combined with this one, both can be used to kickstart a new article dedicated to pharmaceutical prices and the various cost containment policies that exist, including ERP but not only.[2] Also, essential medicines (and their cost) is a central concept that is nicely covered by the Lancet commissioned paper.[3]
Another interesting bit of info: "A costing model was developed on the basis of disease prevalence, current or projected consumption of medicines, and international reference prices. Using two consumption scenarios, the Commission estimated that between US$77·4 and $151·9 billion (or $13 to $25 per capita) is required to fi nance a basic package of 201 essential medicines (378 dosage forms) in all LMICs. Yet in 2010, the majority of low-income countries (LICs) and 13 out of 47 middle-income countries, spent less than $13 per capita on pharmaceuticals. Thus, the Commission confirmed that many people worldwide do not have access to even a limited basket of essential medicines."[3]
Another great document about how to select medicine price data sources.[4]
And this one about methodological issues of international prices comparisons.[5]
Monograph of guidelines for price studies from specialists, reviews the state-of-the-art of the methods but also studies in various regions of the world, it's a gold mine for anyone interested in medicines prices.[6]

References

  1. ^ Ding, Min; Eliashberg, Jehoshua; Stremersch, Stefan (2013). Innovation and Marketing in the Pharmaceutical Industry: Emerging Practices, Research, and Policies. Springer Science & Business Media. ISBN 978-1-4614-7801-0.
  2. ^ Vogler, Sabine (2019). "Pharmaceutical Pricing Policies". Encyclopedia of Pharmacy Practice and Clinical Pharmacy. Academic Press. pp. 188–201. ISBN 978-0-12-812736-0.
  3. ^ a b Wirtz, VJ; Hogerzeil, HV; Gray, AL; Bigdeli, M; de Joncheere, CP; Ewen, MA; Gyansa-Lutterodt, M; Jing, S; Luiza, VL; Mbindyo, RM; Möller, H; Moucheraud, C; Pécoul, B; Rägo, L; Rashidian, A; Ross-Degnan, D; Stephens, PN; Teerawattananon, Y; 't Hoen, EF; Wagner, AK; Yadav, P; Reich, MR (28 January 2017). "Essential medicines for universal health coverage". Lancet (London, England). 389 (10067): 403–476. doi:10.1016/S0140-6736(16)31599-9. PMID 27832874.
  4. ^ Vogler, Sabine; Schneider, Peter (1 January 2019). "Chapter 8 - Medicine Price Data Sources". Medicine Price Surveys, Analyses and Comparisons. Academic Press: 247–268. doi:10.1016/B978-0-12-813166-4.00014-0.
  5. ^ Danzon, PM; Kim, JD (1998). "International price comparisons for pharmaceuticals. Measurement and policy issues". PharmacoEconomics (Review). 14 Suppl 1: 115–28. doi:10.2165/00019053-199814001-00014. PMID 10186473.
  6. ^ Vogler, Sabine (2018). Medicine Price Surveys, Analyses and Comparisons: Evidence and Methodology Guidance. Academic Press. ISBN 978-0-12-813212-8.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:External_reference_pricing&oldid=930320751"